Analysed VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ) News Sources
Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
22-04-2026
yahoo.com
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
08-05-2026
yahoo.com
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
12-05-2026
yahoo.com
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
14-05-2026
yahoo.com
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?
19-05-2026
yahoo.com
What is the current price of VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ)?
The current price of VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ) is $0.6241.
VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ) absolute price change since previous trading day?
The absolute price change of VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ) since the previous trading day is $-0.0126.
VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ) percentage price change since previous trading day?
The percentage price change of VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ) since the previous trading day is -1.979%.
What is the most recent average sentiment score for VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ)?
The most recent average sentiment score for VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ)?
The most recent sentiment for VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ) is .
SEC-8K** Filing Available For VISTAGEN THERAPEUTICS INC (VTGN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.